Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmacyclics has presented results from two phase III trials, which indicate that Xcytrin Injection combined with whole brain radiation therapy significantly prolonged time to neurologic progression in lung cancer patients with brain tumors.
Subscribe to our email newsletter
The research described pooled results from two phase III trials evaluating the safety and efficacy of whole brain radiation therapy (WBRT) alone to WBRT plus Xcytrin in non-small cell lung cancer (NSCLC) patients with brain metastases.
“These data demonstrate that Xcytrin, used in combination with whole brain radiation therapy, may significantly improve neurologic outcomes in patients with brain metastases from non-small cell lung cancer,” said William Shapiro, chief of the neuro-oncology division of neurology at the Barrow Neurological Institute.
“We are moving forward with preparation of a new drug application with the FDA and anticipate filing by the end of the calendar year,” said Richard Miller, president and CEO of Pharmacyclics.